ライフサイエンスコーパス: contrast media

1 n permeability values generated with the two contrast media.

2 between thrombus-related events and type of contrast media.

3 lopment of new classes of magnetic resonance contrast media.

4 c LOCM alone, and eight with combinations of contrast media.

5 d with intravenously and orally administered contrast media.

6 r iodixanol 270 or low-osmolar iopromide 300 contrast media.

7 ion) ranked similarly for ionic and nonionic contrast media.

8 tal ADEs are uncommon relative to the use of contrast media.

9 associated with LOCM than with conventional contrast media.

10 eased incidence of adverse events related to contrast media.

11 ease was associated with the use of nonionic contrast media.

12 unction (n = 307) who received intravascular contrast media.

13 submitted were reviewed for use of iodinated contrast media.

14 ere measured during power injection of three contrast media.

15 risk of thrombosis with the use of nonionic contrast media.

16 zed to receive nonionic or ionic low osmolar contrast media.

17 e aware of the risk factors for reactions to contrast media.

18 Its weakness is its low sensitivity towards contrast media.

19 w studies were done in patients receiving IV contrast media.

20 te dimeglumine in patients who received both contrast media.

21 nce (MR) imaging with two different doses of contrast media.

22 ivity of ionic and non-ionic preparations of contrast media.

23 nistration of iodinated and tungsten cluster contrast media.

24 of the load was due to persistent iodinated contrast media.

25 e a simple strategy to define a safe dose of contrast media.

26 ac MR imaging with an emphasis on the use of contrast media.

27 mately 3.6 times higher with all low-osmolar contrast media (2.3%) than with high-osmolar media (0.6%

28 9%), iodinated or magnetic resonance imaging contrast media (4.2%), immunotherapy and vaccines (3.9%)

29 he requirement of administration of multiple contrast media ((99m)Tc-SC and isosulfan blue), unwieldy

30 Contrast media administered during cardiac catheterizati

31 hyperenhanced and hypoenhanced regions after contrast media administration.

32 One hundred ninety-eight gadolinium-based contrast media administrations (99 with gadoxetate disod

33 d antiplatelet effects of ionic and nonionic contrast media after angiographic or clinical outcomes i

34 t reduction in CIN risk with the iso-osmolar contrast media agent iodixanol compared with a diverse g

35 Manganese-based contrast media allowed precise labeling of viable cardio

36 were associated with use of high-osmolality contrast media alone, 32 with ionic LOCM alone, 214 with

37 ce) by using extracellular and blood pool MR contrast media and after death.

38 ly ill patients commonly depend on iodinated contrast media and consequently pose the risk of contras

39 y/vascular interventions depend on iodinated contrast media and consequently pose the risk of contras

40 x CT examination, with use of oral and colon contrast media and contiguous, thin-collimation, helical

41 common complication of procedures requiring contrast media and is associated with increased short- a

42 sing hyperpolarized proton and carbon-13 MRI contrast media and low-field (47.5 mT) preclinical scale

43 ate the cardiovascular effect of iso-osmolar contrast media and the image quality achieved.

44 Overall adverse events related to contrast media and those for which treatment was necessa

45 ibiotics, cardiovascular drugs, painkillers, contrast media, and antiepileptic drugs have been record

46 ssessed by a technician blinded to the study contrast media, and clinical events were monitored by an

47 s, antimycotics, antivirals, iodinated X-ray contrast media, antiinflamatory, cytostatics, diuretics,

48 ionic and non-ionic preparations of the MRI contrast media are able to induce mast cell degranulatio

49 Excess volumes of contrast media are associated with renal complications i

50 Iodine contrast media are essential components of many imaging

51 Because contrast media are excreted by the kidney, we hypothesiz

52 Life-threatening reactions to radiographic contrast media are rare.

53 In particular, these contrast media are well tolerated in patients with renal

54 Nontherapeutical agents, such as contrast media, are also involved.

55 e mast cells markedly more weakly than ionic contrast media at identical concentration.

56 rees ) during 1 hour after administration of contrast media by using a 1.5-T MR unit.

57 Both contrast media caused similarly small but statistically

58 ute phase begins upon exposure to gadolinium contrast media, characterized by a systemic inflammatory

59 iate hypersensitivity reactions to iodinated contrast media (CM) are common.

60 ere assessed at 2, 6, 24, and 48 hours after contrast media (CM) exposure in 458 high-risk patients (

61 spectively develop individualized low-volume contrast media (CM) protocols adapted to tube voltage in

62 vastatin group (80 mg within 24 hours before contrast media [CM] exposure; n=202) or (2) the control

63 With high-osmolar contrast media compared with the three noncharged low-os

64 suffering from chronic kidney disease (CKD), contrast media compatible with renal impairment is sorel

65 o correlate with the area under the curve of contrast media concentration over time.

66 Pioneers and pathfinders in the field of contrast media development and radiologic procedures hel

67 n signal attenuation at equilibrium state of contrast media distribution (10 minutes) was significant

68 To detect extravasation of contrast media during mechanical power injection at dyna

69 of antibiotic and antimycotic agents to ERC contrast media efficiently reduced post-ERC infectious e

70 Purpose To develop a dual-energy contrast media-enhanced computed tomographic (CT) protoc

71 ce increasing due to an increasing number of contrast media-enhanced radiological procedures being pe

72 puted tomography (CT), before and after i.v. contrast media enhancement.

73 s of intravenously administered radiographic contrast media fail to demonstrate renal damage.

74 olarized (129)Xe and (3)He are gases used as contrast media for magnetic resonance imaging that provi

75 ide (Ta2O5) nanoparticles (NPs) as new X-ray contrast media for microcomputed tomography (muCT) imagi

76 have renal insufficiency and are exposed to contrast media formulated with gadolinium.

77 %) of 105 607 injections of gadolinium-based contrast media (gadopentetate dimeglumine, 31 540; gadob

78 between the iodixanol 270 and iopromide 300 contrast media groups (469 HU +/- 167 vs 447 HU +/- 166,

79 The osmotic characteristics of contrast media have been a significant focus in many inv

80 Echocardiographic contrast media have been used to assess myocardial perfu

81 Technological progress and novel contrast media have resulted in optoacoustic imaging bei

82 nistration of either LOCM or high-osmolality contrast media (HOCM) were reviewed.

83 cumented side effect of the use of iodinated contrast media (ICM) administered intravenously.

84 screening for the detection of six iodinated contrast media (ICM) and their phototransformation produ

85 Iodinated contrast media (ICM) are commonly administered pharmaceu

86 ogical wastewater treatment, iodinated X-ray contrast media (ICM) have been detected in municipal was

87 The transformation of the iodinated X-ray contrast media (ICM) iopamidol, iopromide, iohexol, iome

88 g the post-treatments consisted of iodinated contrast media (ICM).

89 stem is able to discriminate gold and iodine contrast media in different organs in vivo.

90 Separation of two vascular contrast media in different vascular phases enabled acqu

91 lantation, prevention by avoiding gadolinium contrast media in patients with chronic kidney disease i

92 application of antimicrobial agents into ERC contrast media in preventing post-ERC infectious complic

93 ring complication associated with the use of contrast media in radiological studies.

94 PA) and necrosis-specific (mesoporphyrin) MR contrast media in rats.

95 dinated and gadolinium (Gd)-based CT and MRI contrast media in renally compromised patients.

96 o 90 patients who were administered the same contrast media in reverse order (180 patients).

97 n appropriate volumes are useful alternative contrast media in selected high-risk patients undergoing

98 rostheses that had inlays of water, fat, and contrast media in the pelvis was used to optimize the IF

99 hancement of selected pairs of complementary contrast media in vivo.

100 The use of gadolinium contrast-media in MRI studies increases both the reliabi

101 The most important adverse effects of contrast media include hypersensitivity reactions, thyro

102 junction is achieved with a quadruple-phase contrast media injection protocol.

103 available high-osmolar and four low-osmolar contrast media (ioxaglate, iohexol, iopamidol, and iover

104 e overall safety profile of gadolinium-based contrast media is excellent.

105 s for pediatric anaphylaxis from intravenous contrast media is insufficient.

106 romising new developments include blood pool contrast media, labeling of myocardial precursor cells,

107 ast medium (IOCM) iodixanol with low-osmolar contrast media (LOCM) and to identify predictors of cont

108 teria, suggesting that intravenous iodinated contrast media may not be the causative agent in diminis

109 Novel contrast media may potentially be used to detect pathoph

110 Evaluation of the enhancement after contrast media (n=29) showed mean enhancement +/-SD of 2

111 ne the influence of the gadolinium-based MRI contrast media on histamine release from mast cells and

112 The influence of the classical, iodine-based contrast media on mastocyte degranulation has been fully

113 Purpose To assess the effect of intravenous contrast media on renal function in neonates.

114 the phrases "contrast," "contrast medium," "contrast media," or "radiocontrast" and any of the words

115 Clear separation of each of the contrast media pairs was seen in the phantom and in both

116 ostprocedural heparin, and a lower amount of contrast media per case (P<0.05).

117 rs and postprocedural heparin, and amount of contrast media per case.

118 l medical status, previous administration of contrast media, procedural information, occurrence and c

119 Blood-pool contrast media provide persistent signal enhancement in

120 Albumin-binding gadolinium-based contrast media provided a longer imaging window, but inf

121 ry angioplasty, the use of ionic low osmolar contrast media reduces the risk of ischemic complication

122 after angioplasty, patients receiving ionic contrast media reported significantly fewer symptoms of

123 n after incubation with the solutions of MRI contrast media results from non-specific osmotic stimula

124 IV saline in patients receiving low-osmolar contrast media (RR, 0.65 [CI, 0.33 to 1.25]; low SOE), s

125 Iodide-containing medications and contrast media should be avoided in patients with functi

126 Therefore, low osmolar ionic contrast media should be strongly considered when perfor

127 logies, safety issues related to new imaging contrast media, standardisation of image acquisition acr

128 It was also proved that the non-ionic MRI contrast media stimulate mast cells markedly more weakly

129 rosmotic, orally administered, water-soluble contrast media such as Gastrografin are theoretically ca

130 e used to monitor the first-pass dynamics of contrast media, thus defining selective regional myocard

131 hyperthyroidism after injection of iodinated contrast media to evaluate a left hemipelvis mass.

132 The ratio of the volume of contrast media to the creatinine clearance (V/CrCl) has

133 The contrast media varied in viscosity from a thin barium li

134 However, contrast media volume and osmolality may affect the degr

135 Intrathecal injection of nonionic contrast media was associated with 235 reported serious,

136 The use of antimicrobials in contrast media was associated with a significant decreas

137 ncomycin, gentamicin and fluconazol into ERC contrast media was evaluated in a case-control design.

138 Contrast media were administered orally and by means of

139 d intravenous and bismuth subsalicylate oral contrast media were administered.

140 c-like reactions related to gadolinium-based contrast media were assessed 2 years before and 3.5 year

141 nonfatal ADEs; intrathecal ionic [corrected] contrast media were associated with 14 such reported ADE

142 High-osmolality contrast media were associated with 512 serious, nonfata

143 ta from 1980 to 1984, when only high-osmolar contrast media were available.

144 nd of radiological signs that do not require contrast-media were analyzed.

145 on can be achieved with iso- and low-osmolar contrast media when it is injected at the same iodine de

146 heters should tolerate power injection of CT contrast media with peak pressures remaining below the m